NO20085051L - Behandling av gastrointestinale forstyrrelser med CGRP-antagonister - Google Patents

Behandling av gastrointestinale forstyrrelser med CGRP-antagonister

Info

Publication number
NO20085051L
NO20085051L NO20085051A NO20085051A NO20085051L NO 20085051 L NO20085051 L NO 20085051L NO 20085051 A NO20085051 A NO 20085051A NO 20085051 A NO20085051 A NO 20085051A NO 20085051 L NO20085051 L NO 20085051L
Authority
NO
Norway
Prior art keywords
treatment
gastrointestinal disorders
cgrp antagonists
disorders
cgrp
Prior art date
Application number
NO20085051A
Other languages
English (en)
Norwegian (no)
Inventor
Klaus Rudolf
Kirsten Arndt
Gerhard Schaenzle
Thierry Bouyssou
Stephan Georg Mueller
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20085051(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20085051L publication Critical patent/NO20085051L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20085051A 2006-06-08 2008-12-04 Behandling av gastrointestinale forstyrrelser med CGRP-antagonister NO20085051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08
PCT/EP2007/055543 WO2007141285A1 (fr) 2006-06-08 2007-06-06 Traitement de troubles gastro-intestinaux avec des antagonistes cgrp

Publications (1)

Publication Number Publication Date
NO20085051L true NO20085051L (no) 2008-12-19

Family

ID=37101671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085051A NO20085051L (no) 2006-06-08 2008-12-04 Behandling av gastrointestinale forstyrrelser med CGRP-antagonister

Country Status (19)

Country Link
US (2) US20080139591A1 (fr)
EP (2) EP2029233A2 (fr)
JP (2) JP2009539800A (fr)
KR (1) KR20090021214A (fr)
CN (1) CN101500653A (fr)
AR (2) AR061272A1 (fr)
AU (1) AU2007255395A1 (fr)
BR (1) BRPI0712492A2 (fr)
CA (2) CA2654048A1 (fr)
CL (2) CL2007001663A1 (fr)
EA (1) EA200802381A1 (fr)
EC (1) ECSP089025A (fr)
IL (1) IL195712A0 (fr)
MX (1) MX2008015562A (fr)
NO (1) NO20085051L (fr)
PE (2) PE20080370A1 (fr)
TW (2) TW200815010A (fr)
UY (2) UY30398A1 (fr)
WO (2) WO2007141285A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090021214A (ko) * 2006-06-08 2009-02-27 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ-길항제에 의한 위장 장애의 치료
WO2010070023A2 (fr) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) * 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3366286A1 (fr) 2017-02-22 2018-08-29 Johannes Keller Composés destinés au traitement de septicémie
WO2020146527A1 (fr) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
CA3077973A1 (fr) 2020-04-06 2021-10-06 H. Lundbeck A/S Traitement du symptome le plus perturbant associe a la migraine au moyen d`anticorps anti-cgrp

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US20080070239A1 (en) * 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP1770091A1 (fr) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CN101146799A (zh) * 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (fr) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP selectionnés, leur procedé de préparation ainsi que leur utilisation comme medicaments
EP1770086A1 (fr) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP selectionnés, leur procédé de préparation ainsi que leur utilisation comme médicaments
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
KR20090021214A (ko) * 2006-06-08 2009-02-27 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ-길항제에 의한 위장 장애의 치료

Also Published As

Publication number Publication date
TW200808791A (en) 2008-02-16
AU2007255395A1 (en) 2007-12-13
WO2007141284A3 (fr) 2008-03-06
AR061271A1 (es) 2008-08-13
US20080139591A1 (en) 2008-06-12
ECSP089025A (es) 2009-01-30
EP2029234A1 (fr) 2009-03-04
MX2008015562A (es) 2008-12-17
PE20080370A1 (es) 2008-06-13
US20080139537A1 (en) 2008-06-12
WO2007141284A2 (fr) 2007-12-13
PE20080153A1 (es) 2008-04-14
AR061272A1 (es) 2008-08-13
BRPI0712492A2 (pt) 2012-08-21
EP2029233A2 (fr) 2009-03-04
JP2009539799A (ja) 2009-11-19
UY30398A1 (es) 2008-01-31
CL2007001663A1 (es) 2008-01-25
JP2009539800A (ja) 2009-11-19
TW200815010A (en) 2008-04-01
KR20090021214A (ko) 2009-02-27
IL195712A0 (en) 2009-09-01
CA2654047A1 (fr) 2007-12-13
CL2007001662A1 (es) 2008-01-25
WO2007141285A1 (fr) 2007-12-13
EA200802381A1 (ru) 2009-06-30
UY30399A1 (es) 2008-01-31
CA2654048A1 (fr) 2007-12-13
US7807666B2 (en) 2010-10-05
CN101500653A (zh) 2009-08-05

Similar Documents

Publication Publication Date Title
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
WO2008008551A3 (fr) Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
DE602007008434D1 (de) Rezeptoren
IL185422A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
SI2878297T1 (sl) Zdravila za zdravljenje ali preprečevanje fibroznih bolezni
WO2007019251A3 (fr) Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
WO2008070129A3 (fr) Compositions et procédés pour le traitement de maladie inflammatoire
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
DK2310003T3 (da) Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv
DK2001456T3 (da) Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
TW200744584A (en) Use of mGluR5 antagonists (ESP. AFQ056) in GI (ESP. GERD)
EP1899318A4 (fr) Nouveaux derives d'azetidine utiles en tant qu'antagonistes des recepteurs des neurokinines employes pour le traitement des maladies gastro-intestinales

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application